Market Place
Sourcing Support
Kairos Pharma Ltd. Completes Safety Arm of ENV105 Trial
31 Mar 2025 //
BUSINESSWIRE
Zydus gets USFDA nod to produce prostate cancer treatment
18 Mar 2025 //
ECONOMICTIMES
J&J`s Erleada shows survival edge over Xtandi in real-world study
02 Oct 2024 //
FIERCE PHARMA
ORIC Pharmaceuticals Reports Q2 2024 Results And Operational Updates
12 Aug 2024 //
GLOBENEWSWIRE
Johnson & Johnson 1Q Results
20 May 2024 //
CONTRACT PHARMA
ERLEADA® Combo Shows 100% Biochemical Control Post-Prostatectomy
03 May 2024 //
PR NEWSWIRE
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105
30 Jan 2024 //
GLOBENEWSWIRE
Erleada Approved as the Only Androgen Receptor Inhibitor in Canada
10 Aug 2023 //
NEWSWIRE
Erleada, First Next-Generation Androgen Receptor Inhibitor Available in U.S.
03 Apr 2023 //
PR NEWSWIRE
Hope as FDA approves injectable drug for resistant HIV
03 Jan 2023 //
NATION
J&J takes Aurobindo to court over potential Erleada generic
01 Jun 2022 //
ENDPTS
FDA Confirms Para IV Patent Litigation for Apalutamide tablets.
06 Apr 2022 //
FDA
New ERLEADA Analysis Demonstrates Rapid, Deep PSA Response in mCSPC
14 Feb 2022 //
PRESS RELEASE
J&J to divide into consumer health and pharmaceutical businesses
15 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
NICE changes its mind on Janssen’s Erleada
08 Sep 2021 //
PHARMA TIMES
FDA finalizes guidance on metastasis-free survival as an endpoint
06 Aug 2021 //
RAPS
Janssen’s Erleada maintains quality of life for prostate cancer patients
27 May 2021 //
PHARMATIMES
NICE rejects Janssen`s prostate cancer drug Erleada
21 May 2021 //
PHARMAFILE
Janssen Presents Results from Phase 3 ACIS Study in Patients
09 Feb 2021 //
BUSINESSWIRE
Kangpu to Present Two Posters at the 2020 (AACR) Annual Meeting
17 Jun 2020 //
PRNASIA
Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic
29 May 2020 //
PRNEWSWIRE
J&J`s prostate cancer med Erleada extends lives by 14 months
13 May 2020 //
FIERCE PHARMA
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients
13 May 2020 //
PRNEWSWIRE
WHO to accelerate research and innovation for new coronavirus
12 Feb 2020 //
BIOSPECTRUMASIA
Bayer’s Nubeqa wins key survival marker in prostate cancer
31 Jan 2020 //
FIERCE PHARMA
European Commission expands use for Janssen’s Erleada
29 Jan 2020 //
BUSINESSWIRE
Janssen`s Erleada expanded in Europe to cover metastatic hormone prostate cancer
29 Jan 2020 //
PHARMAFILE
J&J`s Erleada misses its mark, but execs see reason to cheer
28 Sep 2019 //
FIERCE PHARMA
Janssen gets US FDA approval for Erleada to treat sensitive prostate cancer
27 Sep 2019 //
PHARMABIZ
US FDA approves Janssen`s Erleada for castration-sensitive prostate cancer
20 Sep 2019 //
PHARMABIZ
J&J finds competitive edge with latest Erleada approval
19 Sep 2019 //
BIOPHARMADIVE
FDA Collaborates With Health Canada, Australia to Approve New Cancer Drugs
18 Sep 2019 //
RAPS
Pfizer, Astellas` Xtandi racks up more data for new prostate cancer approval
03 Jun 2019 //
FIERCE PHARMA
What to watch for, including Keytruda, Lynparza, KRAS and more
31 May 2019 //
FIERCE PHARMA
J&J pads case for new Erleada use with prostate cancer survival data
31 May 2019 //
FIERCE PHARMA
FDA accepts J&J`s Erleada for real-time review
03 May 2019 //
FIERCE PHARMA
FDA tags Bayer’s prostate cancer drug for priority review as drugmaker gears up
30 Apr 2019 //
ENDPTS
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA®
29 Apr 2019 //
PR NEWSWIRE
Janssen-Cilag NV`s Erleada (Apalutamide) Receives Approval in Europe
22 Mar 2019 //
EMA
Bayer and Orion have their work cut out with darolutamide
16 Feb 2019 //
EVALUATE PHARMA
New prostate cancer data puts Bayer drug in line with Pfizer, J&J rivals
15 Feb 2019 //
BIOPHARMA DIVE
Bayer stresses drug`s tolerability in bid for prostate cancer market
15 Feb 2019 //
REUTERS
US IDMC positive recommends Janssen’s Erleada for mCSPC
31 Jan 2019 //
PHARMA-TECH
Johnson & Johnson`s Erleada trial stops early, case for new prostate cancer nod
31 Jan 2019 //
FIERCE PHARMA
Pfizer`s Xtandi blows by J&J`s Erleada with hot start in new prostate cancer
30 Jan 2019 //
FIERCE PHARMA
EU licence granted for Erleada in prostate cancer
18 Jan 2019 //
PHARMA TIMES
J&J pays $500M in cash to grab rights to a new star cancer drug at argenx
03 Dec 2018 //
ENDPTS
EMA committee recommends approval for 4 medicine
20 Nov 2018 //
PHARMABIZ
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide)
16 Nov 2018 //
BUSINESSWIRE
FDA Drafts Guidance on Metastasis-Free Survival Endpoints in Prostate Cancer
13 Nov 2018 //
RAPS
Anvisa approved Janssen-Cilag Farmaceutica`s Erleada for Prostate cancer
20 Oct 2018 //
ANVISA
Pfizer, Astellas’ Xtandi grabs key nod in nonmetastatic cancer
17 Jul 2018 //
FIERCE PHARMA
Erleada Gains First Approval Under New TGA Work Sharing Pilot
06 Jul 2018 //
RAPS
